{"schema_version":"1.0","type":"article","title":"創新藥開發的「死亡之谷」","url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.md","lang":"zh-Hant","date":"2026-04-17","publish_at":"2026-04-17T10:30:00+08:00","updated_at":"2026-04-17","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"創新藥研發最殘酷的地方，不在於它難，而在於你往往在一開始就知道，它極可能失敗，卻還是必須投入多年時間、巨額資本，以及一整個團隊的職業生涯去把它往前推。","key_points":[],"facts":[],"sections":["真正吞噬專案的，從來不只是不夠努力"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Youtube","source":"","date":"","url":""},{"title":"Created in 1982 through the Small Business Innovation Development Act, the Small Business Innovation Research (SBIR) is the nation’s largest innovation program. It provides competitively awarded grants to small high-technology firms with technically sound","source":"","date":"","url":""},{"title":"www.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Introduction - Venture Funding and the NIH SBIR Program - NCBI Bookshelf\"","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Read \"Materials in a New Era: Proceedings of the 1999 Solid State Sciences Committee Forum\" at NAP.edu","source":"","date":"","url":""},{"title":"Read chapter Keynote Address: Unlocking Our Future: The 1999 Solid State Sciences Committee Forum, entitled \"Materials in a New Era,\" was held at the Nati...","source":"","date":"","url":""},{"title":"www.nationalacademies.org","source":"","date":"","url":""},{"title":"\"Read \\\"Materials in a New Era: Proceedings of the 1999 Solid State Sciences Committee Forum\\\" at NAP.edu\"","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Artificial intelligence (AI) can transform drug discovery and early drug development by addressing inefficiencies in traditional methods, which often face high costs, long timelines, and low success rates. In this review we provide an overview of ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Integrating artificial intelligence in drug discovery and early drug development: a transformative approach - PMC\"","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Drug optimization, which improves drug potency/specificity by structure‒activity relationship (SAR) and drug-like properties, is rigorously performed to select drug candidates for clinical trials. However, the current drug optimization may overlook ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety - PMC\"","source":"","date":"","url":""},{"title":"![Dcard 原圖：創新藥開發的「死亡之谷」（圖 4）](images/dcard-04.png","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：創新藥開發的「死亡之谷」（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-01.webp"},{"alt":"Dcard 原圖：創新藥開發的「死亡之谷」（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-02.webp"},{"alt":"Dcard 原圖：創新藥開發的「死亡之谷」（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-03.webp"},{"alt":"Dcard 原圖：創新藥開發的「死亡之谷」（圖 4）","url":"https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-17）。創新藥開發的「死亡之谷」。https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-17-dcard-261315054-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}